paclitaxel (taxol)

URI: https://gptkb.org/entity/paclitaxel_(taxol)

GPTKB entity

Statements (50)

Predicate	Object
gptkbp:instanceOf	natural product antineoplastic agent mitotic inhibitor
gptkbp:administeredBy	intravenous infusion
gptkbp:ATCCode	L01CD01
gptkbp:brand	gptkb:Abraxane gptkb:Taxol Onxol
gptkbp:CASNumber	33069-62-4
gptkbp:chemicalFormula	C47H51NO14
gptkbp:contraindication	neutrophil counts < 1,500/mm³ severe hypersensitivity to paclitaxel
gptkbp:derivedFrom	gptkb:Pacific_yew_tree
gptkbp:discoveredBy	gptkb:Mansukh_C._Wani gptkb:Monroe_E._Wall
gptkbp:discoveredIn	1971
gptkbp:eliminationHalfLife	5.8 to 24 hours
gptkbp:FDAApproved	1992
gptkbp:firstMarketedBy	gptkb:Bristol-Myers_Squibb
https://www.w3.org/2000/01/rdf-schema#label	paclitaxel (taxol)
gptkbp:IUPACName	(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-11-acetoxy-12-(benzoyloxy)-1,2a,6,9,12,12a-hexahydroxy-4,8,13,13-tetramethyl-5-oxo-4,4a,5,6,7,8,9,10,11,12,12a,12b-dodecahydro-2H,6H,12H-oxeto[2,3-d][1]benzopyran-6-yl benzoate
gptkbp:KEGGID	D05367
gptkbp:legalStatus	prescription only
gptkbp:mechanismOfAction	stabilizes microtubules prevents cell division
gptkbp:MeSH_ID	gptkb:D017360
gptkbp:metabolism	gptkb:CYP2C8 gptkb:CYP3A4 liver
gptkbp:molecularWeight	853.9 g/mol
gptkbp:patentExpired	2000
gptkbp:pregnancyCategory	D (US)
gptkbp:producedBy	gptkb:Taxus_brevifolia
gptkbp:PubChem_CID	gptkb:CHEMBL92 36314 DB01229
gptkbp:routeOfAdministration	intravenous
gptkbp:sideEffect	nausea hair loss peripheral neuropathy neutropenia
gptkbp:solubility	practically insoluble in water
gptkbp:toxicity	myelosuppression hypersensitivity reactions
gptkbp:UNII	P88XT4IS4D
gptkbp:usedFor	gptkb:cancer gptkb:Kaposi's_sarcoma
gptkbp:WHOModelListOfEssentialMedicines	included
gptkbp:bfsParent	gptkb:E_Ring
gptkbp:bfsLayer	7